Wuhan Zhongcheng Health Bio-Pharm Technology Co. Ltd. has disclosed aromatic amine compounds acting as Bcr-Abl (Bcr-Abl1) kinase inhibitors reported to be useful for the treatment of neurodegeneration, motor neuron disease, muscular dystrophy, autoimmune disease and inflammation, viral infection, prion infection and cancer.